{"title":"贝达喹啉——一种治疗耐多药结核病的新药","authors":"S. Yadav, G. Rawal","doi":"10.18231/2394-2797.2018.0017","DOIUrl":null,"url":null,"abstract":"The infectious diseases have taken a toll on the rapidly multiplying population of the developing countries. The top three killers being HIV AIDS, TB and malaria. The total number of deaths due to TB is really a cause of concern since a well laid national program is running in most of these countries. However, even in the presence of clear guidelines to treat TB, there has always been a gradual rise in the new cases with few exceptions in some of these resource-constrained countries. The issue becomes graver when the problem of drug-resistant TB also comes into the picture. In the present article, the authors highlight the introduction of the new drug i.e., Bedaquiline in India to counter the problem of multidrug-resistant TB.","PeriodicalId":13889,"journal":{"name":"International Journal of Pharmaceutical Chemistry and Analysis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bedaquiline –A new drug against multidrug-resistant tuberculosis\",\"authors\":\"S. Yadav, G. Rawal\",\"doi\":\"10.18231/2394-2797.2018.0017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The infectious diseases have taken a toll on the rapidly multiplying population of the developing countries. The top three killers being HIV AIDS, TB and malaria. The total number of deaths due to TB is really a cause of concern since a well laid national program is running in most of these countries. However, even in the presence of clear guidelines to treat TB, there has always been a gradual rise in the new cases with few exceptions in some of these resource-constrained countries. The issue becomes graver when the problem of drug-resistant TB also comes into the picture. In the present article, the authors highlight the introduction of the new drug i.e., Bedaquiline in India to counter the problem of multidrug-resistant TB.\",\"PeriodicalId\":13889,\"journal\":{\"name\":\"International Journal of Pharmaceutical Chemistry and Analysis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutical Chemistry and Analysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/2394-2797.2018.0017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Chemistry and Analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/2394-2797.2018.0017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bedaquiline –A new drug against multidrug-resistant tuberculosis
The infectious diseases have taken a toll on the rapidly multiplying population of the developing countries. The top three killers being HIV AIDS, TB and malaria. The total number of deaths due to TB is really a cause of concern since a well laid national program is running in most of these countries. However, even in the presence of clear guidelines to treat TB, there has always been a gradual rise in the new cases with few exceptions in some of these resource-constrained countries. The issue becomes graver when the problem of drug-resistant TB also comes into the picture. In the present article, the authors highlight the introduction of the new drug i.e., Bedaquiline in India to counter the problem of multidrug-resistant TB.